InnoCare Pharma (9969) Q4 2025 earnings summary

Executive summary

• Achieved first annual profitability in 2025 with net profit of RMB 644.2 million, reversing a prior loss, driven by 135% year-over-year revenue growth, strong drug sales, and global licensing revenue.

• Total revenue reached RMB 2.38 billion, up 135% year-over-year, led by commercial product ramp-up, BD transactions, and major launches in oncology and autoimmune diseases.

• Maintained robust cash reserves, with balances reported at RMB 7.8 billion at year-end, supporting ongoing R&D, globalization, and pipeline expansion.

• Advanced internationalization strategy through major licensing deals and strategic collaborations, expanding global presence and pipeline value.

• Multiple regulatory approvals and pipeline expansions in oncology, autoimmune, and solid tumors, with significant late-stage clinical progress.

Financial highlights

• Drug/product sales reached RMB 1.44 billion, up 43.4% year-over-year, with gross profit increasing 150.7% to RMB 2,183.8 million and gross margin rising to 92.0%.

• Diluted EPS was RMB 0.38 for 2025, turning positive from a loss per share in 2024.

• R&D expenses were RMB 952 million, up 16.9% year-over-year, reflecting strategic investment in innovation.

• Positive operating cash flow achieved for the first time.

• Adjusted profit for the year was RMB 675.4 million, excluding non-cash items.

Outlook and guidance

• Drug sales expected to grow by more than 35% in 2026, with multiple late-stage assets approaching regulatory submissions and commercialization.

• Management anticipates accelerated revenue growth, improved operating leverage, and enhanced earnings visibility as new products enter the market.

• Confident in sustaining breakeven and profitability through 2026 and 2027, even without new BD deals.

• R&D expenses projected to grow around 20% in 2026, with no near-term financing pressure.

• Continued focus on globalization, selective out-licensing, and regional partnerships to maximize asset value.